123 related articles for article (PubMed ID: 23686896)
1. Cardiovascular risk and bone loss in men undergoing androgen deprivation therapy for non-metastatic prostate cancer: implementation of standardized management guidelines.
Cheung AS; Pattison D; Bretherton I; Hoermann R; Lim Joon D; Ho E; Jenkins T; Hamilton EJ; Bate K; Chan I; Zajac JD; Grossmann M
Andrology; 2013 Jul; 1(4):583-9. PubMed ID: 23686896
[TBL] [Abstract][Full Text] [Related]
2. Bone complications among prostate cancer survivors: long-term follow-up from the prostate cancer outcomes study.
Morgans AK; Fan KH; Koyama T; Albertsen PC; Goodman M; Hamilton AS; Hoffman RM; Stanford JL; Stroup AM; Penson DF
Prostate Cancer Prostatic Dis; 2014 Dec; 17(4):338-42. PubMed ID: 25134939
[TBL] [Abstract][Full Text] [Related]
3. Metabolic Changes in Androgen-Deprived Nondiabetic Men With Prostate Cancer Are Not Mediated by Cytokines or aP2.
Gagliano-Jucá T; Burak MF; Pencina KM; Li Z; Edwards RR; Travison TG; Basaria S
J Clin Endocrinol Metab; 2018 Oct; 103(10):3900-3908. PubMed ID: 30032274
[TBL] [Abstract][Full Text] [Related]
4. The implications of baseline bone-health assessment at initiation of androgen-deprivation therapy for prostate cancer.
Kirk PS; Borza T; Shahinian VB; Caram MEV; Makarov DV; Shelton JB; Leppert JT; Blake RM; Davis JA; Hollenbeck BK; Sales A; Skolarus TA
BJU Int; 2018 Apr; 121(4):558-564. PubMed ID: 29124881
[TBL] [Abstract][Full Text] [Related]
5. Approaches to Prevent and Manage Cardiovascular Disease in Patients Receiving Therapy for Prostate Cancer.
Ng CT; Bonilla HMG; Bryce AH; Singh P; Herrmann J
Curr Cardiol Rep; 2023 Aug; 25(8):889-899. PubMed ID: 37490155
[TBL] [Abstract][Full Text] [Related]
6. Influence of age on incident diabetes and cardiovascular disease in prostate cancer survivors receiving androgen deprivation therapy.
Morgans AK; Fan KH; Koyama T; Albertsen PC; Goodman M; Hamilton AS; Hoffman RM; Stanford JL; Stroup AM; Resnick MJ; Barocas DA; Penson DF
J Urol; 2015 Apr; 193(4):1226-31. PubMed ID: 25451829
[TBL] [Abstract][Full Text] [Related]
7. Effects of androgen deprivation therapy on elderly men with high-risk prostate cancer: PROSARC observational study.
Legido-Gómez Ó; Rico-Marco S; Lorenzo-Sánchez MV; Navarro-Jiménez S; Tárraga-Honrubia MA; Martínez-Ruiz J; Giménez-Bachs JM; Donate-Moreno MJ; Díaz de Mera-Sánchez-Migallón I; Segura-Martín M; Alcantud-Córcoles R; Abizanda-Soler P; Salinas-Sánchez AS
Actas Urol Esp (Engl Ed); 2024 May; 48(4):304-310. PubMed ID: 38373481
[TBL] [Abstract][Full Text] [Related]
8. Intermittent Hormonal Therapy in Biochemical Recurrence of Prostate Cancer Is Worth Considering Because of Mitigation of Cardiovascular Events and Reduction of Other Effects.
Kwon DH; Aggarwal RR
Eur Urol Focus; 2023 May; 9(3):405-406. PubMed ID: 36690547
[TBL] [Abstract][Full Text] [Related]
9. Perspectives on the Cardiovascular and Metabolic Effects of Androgen Deprivation Therapy in Prostate Cancer.
Sentana-Lledo D; Morgans AK
Curr Oncol Rep; 2024 Mar; 26(3):299-306. PubMed ID: 38376624
[TBL] [Abstract][Full Text] [Related]
10. Exergaming Improves Cardiac Risk Factors in Prostate Cancer Patients: A Single-Blinded Randomized Controlled Trial.
Villumsen BR; Frystyk J; Jørgensen MG; Hørdam B; Borre M
Games Health J; 2024 Apr; 13(2):93-99. PubMed ID: 37917926
[No Abstract] [Full Text] [Related]
11. Nutrition Guidance for Patients on Androgen Deprivation Therapy.
Kenfield SA; Van Blarigan EL; Graff RE; Borno HT; Macaire G; Chan JM
Eur Urol Focus; 2023 May; 9(3):427-430. PubMed ID: 36935290
[TBL] [Abstract][Full Text] [Related]
12. Estrogenic side effects of androgen deprivation therapy.
Guise TA; Oefelein MG; Eastham JA; Cookson MS; Higano CS; Smith MR
Rev Urol; 2007; 9(4):163-80. PubMed ID: 18231613
[TBL] [Abstract][Full Text] [Related]
13. Optimizing outcomes in men with prostate cancer: the cardiovascular event lowering (CaELo) pathways.
Crawford DE; Albala D; Garnick MB; Hahn AW; Maroni P; McKay RR; Miner M; Orio Ⅲ P; Pandit K; Sellinger S; Yu EY; Eckel RH
Can J Urol; 2024 Apr; 31(2):11820-11825. PubMed ID: 38642459
[TBL] [Abstract][Full Text] [Related]
14. The impact of prostate cancer and hormonal therapy on bone.
Andriole GL
Rev Urol; 2009; 11(4):185-9. PubMed ID: 20111630
[TBL] [Abstract][Full Text] [Related]
15. The need for precision medicine in managing cardiovascular risk for men receiving ADT.
Hahn AW; Koutroumpakis E; Narayan V; Aparicio A
Prostate Cancer Prostatic Dis; 2024 May; ():. PubMed ID: 38796515
[No Abstract] [Full Text] [Related]
16. Adverse effects of androgen deprivation therapy and strategies to mitigate them.
Nguyen PL; Alibhai SM; Basaria S; D'Amico AV; Kantoff PW; Keating NL; Penson DF; Rosario DJ; Tombal B; Smith MR
Eur Urol; 2015 May; 67(5):825-36. PubMed ID: 25097095
[TBL] [Abstract][Full Text] [Related]
17. Muscle and bone effects of androgen deprivation therapy: current and emerging therapies.
Cheung AS; Zajac JD; Grossmann M
Endocr Relat Cancer; 2014 Oct; 21(5):R371-94. PubMed ID: 25056176
[TBL] [Abstract][Full Text] [Related]
18. Addressing the risk and management of cardiometabolic complications in prostate cancer patients on androgen deprivation therapy and androgen receptor axis-targeted therapy: consensus statements from the Hong Kong Urological Association and the Hong Kong Society of Uro-Oncology.
Poon DMC; Tan GM; Chan K; Chan MTY; Chan TW; Kan RWM; Lam MHC; Leung CLH; Wong KCW; Kam KKH; Ng CF; Chiu PKF
Front Oncol; 2024; 14():1345322. PubMed ID: 38357197
[TBL] [Abstract][Full Text] [Related]
19. A review focusing on the role of pyroptosis in prostate cancer.
Liu Z; Kuang S; Chen Q
Medicine (Baltimore); 2023 Dec; 102(50):e36605. PubMed ID: 38115248
[TBL] [Abstract][Full Text] [Related]
20. A review of the objective cognitive function measurements in males receiving hormonal therapy for prostate cancer.
Neerhut T; Shin BNH; Rhee H; Chung E
Investig Clin Urol; 2023 Nov; 64(6):521-540. PubMed ID: 37932563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
